Evidence map›Paper›PMID 34579614›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2021

Recent advance in the discovery of tyrosinase inhibitors from natural sources via separation methods.

Xiao-Wei Zhang, Guang-Li Bian, Pei-Ying Kang, Xin-Jie Cheng, Kai Yan, Yong-Li Liu, Yan-Xia Gao, De-Qiang Li

Open access · goldAbstract readReview
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Fast Screening of Tyrosinase Inhibitors inMolecules (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Bioprospecting ofFrontiers in microbiology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. The Relationship between the ICMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiao-Wei ZhangDepartment of Neurological Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Guang-Li BianDepartment of Pharmacy, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Pei-Ying KangDepartment of Clinical Laboratory, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xin-Jie ChengDepartment of Pharmacy, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Kai YanInstitute for Drug Control of Hebei Province, Shijiazhuang, China.
Yong-Li LiuInstitute for Drug Control of Hebei Province, Shijiazhuang, China.
Yan-Xia GaoInstitute for Drug Control of Hebei Province, Shijiazhuang, China.
De-Qiang LiDepartment of Pharmacy, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNHebei Provincial Center for Disease Control and Prevention · CNSecond Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinase (TYR) inhibitors are in great demand in the food, cosmetic and medical industrials due to their important roles. Therefore, the discovery of high-quality TYR inhibitors is always pursued. Natural products as one of the most important sources of bioactive compounds discovery have been increasingly used for TYR inhibitors screening. However, due to their complex compositions, it is still a great challenge to rapid screening and identification of biologically active components from them. In recent years, with the help of separation technologies and the affinity and intrinsic activity of target enzymes, two advanced approaches including affinity screening and inhibition profiling showed great promises for a successful screening of bioactive compounds from natural sources. This review summarises the recent progress of separation-based methods for TYR inhibitors screening, with an emphasis on the principle, application, advantage, and drawback of each method along with perspectives in the future development of these screening techniques and screened hit compounds.

Indexed as

Drug DiscoveryBiological ProductsDrug Evaluation, PreclinicalEnzyme InhibitorsHumansMolecular StructureMonophenol MonooxygenaseUltrafiltrationBiological ProductsEnzyme InhibitorsMonophenol Monooxygenasenatural productsrapid screeningseparation methodsTyrosinase inhibitors

Identifiers

PMID34579614
PMCPMC8480707
OpenAlexW3204807985

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.